Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02302742 · ClinicalTrials.gov registry record
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
A clinical trial of Breast Cancer and Hereditary Breast and Ovarian Cancer, sponsored by University of Kansas Medical Center.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 11
- Study locations
NCT02302742: Recruiting study of Breast Cancer and Hereditary Breast and Ovarian Cancer, sponsored by University of Kansas Medical Center.
NCT02302742 is a study of Breast Cancer and Hereditary Breast and Ovarian Cancer that is actively recruiting participants, run by University of Kansas Medical Center. The registered enrollment target is 1,500 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (46% lower). The trial reports 11 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02302742, a study of Breast Cancer and Hereditary Breast and Ovarian Cancer, is actively recruiting participants, sponsored by University of Kansas Medical Center.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 11
- Study locations
Study Summary
PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).
Conditions Studied
Study Locations (11)
Kansas
- Hays Medical Center Dreiling-Schmidt Cancer Institute - Hays
- KCCC West - Kansas City
- KCCC Overland Park - Overland Park
- Overland Park Regional Medical Center - Overland Park
- Salina Regional Health Center - Tammy Walker Cancer Center - Salina
- The University of Kansas Cancer Center - Westwood
Missouri
- Universtiy Health - Kansas City
- KCCC South - Kansas City
- Research Medical Center - Kansas City
- KCCC - North - Kansas City
- KCCC Lee's Summit - Lee's Summit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2011-03-22 |
| Est. Completion | 2026-12 |
What NCT02302742 shows while recruiting
NCT02302742 is an observational study that tracks outcomes without assigning an intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (46% lower).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT02302742 lists 11 locations in 2 states (Kansas, Missouri).
Frequently Asked Questions
What is clinical trial NCT02302742 about?
NCT02302742 is a clinical study titled "Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry". PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).
What is the current status of trial NCT02302742?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2011-03-22. Estimated completion is 2026-12.
What conditions does trial NCT02302742 study?
This clinical trial studies the following conditions: Breast Cancer, Hereditary Breast and Ovarian Cancer.
Who is sponsoring clinical trial NCT02302742?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02302742 being conducted?
This trial has 11 study locations across Kansas, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02302742's enrollment target sits among peer trials
1,500 82nd of 1224 higher than 1,141 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI